Our Capital Markets team advised Van Lanschot Kempen N.V., Chardan and KBC Securities on the capital increase of MaaT Pharma for a total amount of €13 million through a private placement.
MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival.
This fundraising will enable Maat Pharma to support its progress towards key value milestones, including market submission for EU approval of MaaT013.
The Goodwin team was led by Guilhem Richard on French law aspects and Edwin O’Connor on US law aspects, and included Mariléna Gryparis and Shanna Kim.